BVT-0139-C250250 µgCHF 150.00
BVT-0139-M0011 mgCHF 450.00
|Synonyms||NSC 359079; BRN 4732638|
|Source/Host Chemicals||Isolated from Streptomyces sp.|
|Purity Chemicals||≥98% (HPLC)|
|Solubility||Soluble in DMSO.|
|Identity||Determined by 1H-NMR.|
|Declaration||Manufactured by BioViotica.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
|Handling Advice||Protect from light when in solution.|
Stable for at least 1 year after receipt when stored at -20°C.
Stock solutions are stable for at least 3 months when stored at -20°C.
After reconstitution, prepare aliquots and store at -20°C.
|Product Specification Sheet|
- Antibiotic. Structurally similar to staurosporine.
- Selective activity against several cancer cell lines.
- DNA intercalator, resulting in catalytic inhibition of topoisomerases I.
- Shows significant antitumor properties in vitro (IC50 = 480 nM against mouse B16 melanoma cells and IC50 = 500 nM against P388 leukemia cells).
- Does not show any inhibitory activity against protein kinases.
- Production and biological activity of rebeccamycin, a novel antitumor agent: J.A. Bush, et al.; J. Antibiot. (Tokyo) 40, 668 (1987)
- Induction of mammalian DNA topoisomerase I mediated DNA cleavage by antitumor indolocarbazole derivatives: Y. Yamashita, at al.; Biochemisty 31, 12069 (1992)
- DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin: C. Bailly, et al.; Biochemistry 36, 3917 (1997)
- Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group: F. Anizon, et al.; J. Med. Chem. 40, 3456 (1997)
- Calories from carbohydrates: energetic contribution of the carbohydrate moiety of rebeccamycin to DNA binding and the effect of its orientation on topoisomerase I inhibition: C. Bailly, et al.; Chem. Biol. 6, 277 (1999)
- Discovery of Antitumor Indolocarbazoles: Rebeccamycin, NSC 655649, and Fluoroindolocarbazoles: B.H. Long, et al.; Curr. Med. Chem. 2, 255 (2002)
- Rebeccamycin derivatives as dual DNA-damaging agents and potent checkpoint kinase 1 inhibitor: C. Marminon, et al.; Mol Pharmacol 74, 1620-1629 (2008)
- Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers: A. Dowlati, et al.; Cancer Chemother Pharmacol 65, 73-78 (2009)
- New progress of researches in carbazole compounds: F. Zhang, et al.; Chinese J. Org. Chem. 30, 783 (2010)